Form 4: Baker Bros. Advisors Report Stock Option Grants for vTv Therapeutics Director

Baker Bros. Advisors LP reports the grant of non-qualified stock options to Dr. Raymond Cheong, a director of vTv Therapeutics Inc., on June 25, 2024.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 regarding transactions in vTv Therapeutics Inc. (VTVT) securities.
• The report details the grant of non-qualified stock options to Dr. Raymond Cheong, a director of VTVT and a full-time employee of Baker Bros. Advisors LP.
• On June 25, 2024, Dr. Cheong received two grants of stock options: one for 6,000 shares and another for 983 shares.
• The options have an exercise price of $17.22 per share and expire on June 25, 2034.
• The 6,000-share options vest in equal monthly installments over three years, while the 983-share options vest on the first anniversary of the grant date, both subject to Dr. Cheong's continued service on the board.
• The filing also clarifies the indirect beneficial ownership of these options by various Baker Bros. entities and individuals, including Julian C. Baker and Felix J. Baker.
• These individuals disclaim beneficial ownership except to the extent of their pecuniary interest.
• The report indicates that Dr. Cheong does not have a direct right to the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing detailing stock option grants, which is generally neutral to positive as it incentivizes management. The sentiment is moderately positive as it reflects standard corporate governance practices.

Positives

• The grant of stock options aligns Dr. Cheong's interests with those of vTv Therapeutics shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This grant is consistent with standard practices for compensating board members.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their director compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The stock option grants could potentially impact shareholders by diluting equity if the options are exercised.
• The grants incentivize the director to act in the best interests of the company, which could benefit shareholders.

Key Dates